Adenoviral-vectored epigraph vaccine elicits robust, durable, and protective immunity against H3 influenza A virus in swine.
Adenoviral-vectored epigraph vaccine elicits robust, durable, and protective immunity against H3 influenza A virus in swine.
复制标题
DOI：
10.3389/fimmu.2023.1143451
复制
发表时间：
2023
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
目前针对猪甲型流感病毒（IAV-S）的疫苗接种方法很少更新，诱导毒株特异性反应，并且保护时间有限。在这里，我们描述了接种腺病毒载体Epigraph疫苗后适应性免疫反应的开始和持续时间。在这项纵向研究中，我们观察到在接种疫苗六个月后，抗体反应仍然保持在保护滴度以上。我们进一步确定了稳定水平的抗原特异性T细胞反应，在没有抗原刺激的情况下仍然可以检测到。抗体同型分析显示，Epigraph疫苗能诱导IgM到IgG的强类转换，而商业比较疫苗不能诱导强抗体类转换。首次接种epigraph疫苗后6个月，接种epigraph疫苗的动物表现出对气管和肺部微观病变发展的显著保护，病毒脱落的持续时间缩短，肺部感染性病毒和病毒抗原的存在降低，并且在攻击后抗原特异性T细胞反应显著恢复。本研究的结果有助于确定与腺病毒载体疫苗相比，接种佐剂全灭活疫苗后适应性免疫反应的动力学，并有助于继续努力创造通用的IAV-S疫苗。
Current methods of vaccination against swine Influenza A Virus (IAV-S) in pigs are infrequently updated, induce strain-specific responses, and have a limited duration of protection. Here, we characterize the onset and duration of adaptive immune responses after vaccination with an adenoviral-vectored Epigraph vaccine. In this longitudinal study we observed robust and durable antibody responses that remained above protective titers six months after vaccination. We further identified stable levels of antigen-specific T cell responses that remained detectable in the absence of antigen stimulation. Antibody isotyping revealed robust class switching from IgM to IgG induced by Epigraph vaccination, while the commercial comparator vaccine failed to induce strong antibody class switching. Swine were challenged six months after initial vaccination, and Epigraph-vaccinated animals demonstrated significant protection from microscopic lesion development in the trachea and lungs, reduced duration of viral shedding, lower presence of infectious virus and viral antigens in the lungs, and significant recall of antigen-specific T cell responses following challenge. The results obtained from this study are useful in determining the kinetics of adaptive immune responses after vaccination with adjuvanted whole inactivated virus vaccines compared to adenoviral vectored vaccines and contribute to the continued efforts of creating a universal IAV-S vaccine.
登录
查看更多内容
在B淋巴细胞缺陷小鼠中对致命流感病毒感染的抗性和恢复。
影响因子：
15.3
作者：
Graham, M B;Braciale, T J
通讯作者：
Braciale, T J
影响因子：
3.7
作者：
Brookes SM;Núñez A;Choudhury B;Matrosovich M;Essen SC;Clifford D;Slomka MJ;Kuntz-Simon G;Garcon F;Nash B;Hanna A;Heegaard PM;Quéguiner S;Chiapponi C;Bublot M;Garcia JM;Gardner R;Foni E;Loeffen W;Larsen L;Van Reeth K;Banks J;Irvine RM;Brown IH
通讯作者：
Brown IH
影响因子：
16.6
作者：
Bullard BL;Corder BN;DeBeauchamp J;Rubrum A;Korber B;Webby RJ;Weaver EA
通讯作者：
Weaver EA
DOI：
10.1056/nejmoa2105290
发表时间：
2021-12-16
期刊：
The New England journal of medicine
影响因子：
--
作者：
Falsey AR;Sobieszczyk ME;Hirsch I;Sproule S;Robb ML;Corey L;Neuzil KM;Hahn W;Hunt J;Mulligan MJ;McEvoy C;DeJesus E;Hassman M;Little SJ;Pahud BA;Durbin A;Pickrell P;Daar ES;Bush L;Solis J;Carr QO;Oyedele T;Buchbinder S;Cowden J;Vargas SL;Guerreros Benavides A;Call R;Keefer MC;Kirkpatrick BD;Pullman J;Tong T;Brewinski Isaacs M;Benkeser D;Janes HE;Nason MC;Green JA;Kelly EJ;Maaske J;Mueller N;Shoemaker K;Takas T;Marshall RP;Pangalos MN;Villafana T;Gonzalez-Lopez A;AstraZeneca AZD1222 Clinical Study Group
通讯作者：
AstraZeneca AZD1222 Clinical Study Group
影响因子：
5.4
作者：
Harui, A;Suzuki, S;Mitani, K
通讯作者：
Mitani, K